• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于肿瘤内基因异质性建模和致癌驱动基因突变功能分析的CRISPR条形码技术

CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations.

作者信息

Guernet Alexis, Mungamuri Sathish Kumar, Cartier Dorthe, Sachidanandam Ravi, Jayaprakash Anitha, Adriouch Sahil, Vezain Myriam, Charbonnier Françoise, Rohkin Guy, Coutant Sophie, Yao Shen, Ainani Hassan, Alexandre David, Tournier Isabelle, Boyer Olivier, Aaronson Stuart A, Anouar Youssef, Grumolato Luca

机构信息

Normandie Univ, UNIROUEN, INSERM, DC2N, 76000 Rouen, France; Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France.

Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

出版信息

Mol Cell. 2016 Aug 4;63(3):526-38. doi: 10.1016/j.molcel.2016.06.017. Epub 2016 Jul 21.

DOI:10.1016/j.molcel.2016.06.017
PMID:27453044
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5537739/
Abstract

Intratumor genetic heterogeneity underlies the ability of tumors to evolve and adapt to different environmental conditions. Using CRISPR/Cas9 technology and specific DNA barcodes, we devised a strategy to recapitulate and trace the emergence of subpopulations of cancer cells containing a mutation of interest. We used this approach to model different mechanisms of lung cancer cell resistance to EGFR inhibitors and to assess effects of combined drug therapies. By overcoming intrinsic limitations of current approaches, CRISPR-barcoding also enables investigation of most types of genetic modifications, including repair of oncogenic driver mutations. Finally, we used highly complex barcodes inserted at a specific genome location as a means of simultaneously tracing the fates of many thousands of genetically labeled cancer cells. CRISPR-barcoding is a straightforward and highly flexible method that should greatly facilitate the functional investigation of specific mutations, in a context that closely mimics the complexity of cancer.

摘要

肿瘤内基因异质性是肿瘤进化并适应不同环境条件的能力基础。利用CRISPR/Cas9技术和特定的DNA条形码,我们设计了一种策略来重现和追踪含有感兴趣突变的癌细胞亚群的出现。我们用这种方法来模拟肺癌细胞对EGFR抑制剂耐药的不同机制,并评估联合药物治疗的效果。通过克服当前方法的内在局限性,CRISPR条形码技术还能够研究大多数类型的基因修饰,包括致癌驱动基因突变的修复。最后,我们将高度复杂的条形码插入特定基因组位置,以此同时追踪数千个基因标记癌细胞的命运。CRISPR条形码技术是一种直接且高度灵活的方法,在紧密模拟癌症复杂性的背景下,应能极大地促进对特定突变的功能研究。

相似文献

1
CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations.用于肿瘤内基因异质性建模和致癌驱动基因突变功能分析的CRISPR条形码技术
Mol Cell. 2016 Aug 4;63(3):526-38. doi: 10.1016/j.molcel.2016.06.017. Epub 2016 Jul 21.
2
Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing.通过CRISPR/Cas9介导的基因组编辑生成携带EGFR T790M突变的肺癌细胞系。
Oncotarget. 2017 May 30;8(22):36331-36338. doi: 10.18632/oncotarget.16752.
3
Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression.通过CRISPR/Cas9对致癌突变等位基因进行选择性破坏可有效诱导肿瘤消退。
Nucleic Acids Res. 2017 Jul 27;45(13):7897-7908. doi: 10.1093/nar/gkx490.
4
Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.表皮生长因子受体突变型肺癌细胞系获得性耐药表皮生长因子受体酪氨酸激酶抑制剂后上皮间质转化。
J Thorac Oncol. 2011 Jul;6(7):1152-61. doi: 10.1097/JTO.0b013e318216ee52.
5
Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.数字PCR分析血浆游离DNA用于非侵入性检测EGFR突变型非小细胞肺癌的耐药机制:与配对肿瘤样本的相关性
Oncotarget. 2015 Oct 13;6(31):30850-8. doi: 10.18632/oncotarget.5068.
6
Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.阿帕替尼增强了表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)对具有EGFR-TKI耐药性的非小细胞肺癌的抗肿瘤活性。
Eur J Cancer. 2017 Oct;84:184-192. doi: 10.1016/j.ejca.2017.07.037. Epub 2017 Aug 17.
7
Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation.综合基因组学方法确定SCRN1的上调是一种与携带致癌EGFR突变的PC9细胞中对厄洛替尼获得性耐药相关的新机制。
Oncotarget. 2016 Mar 22;7(12):13797-809. doi: 10.18632/oncotarget.7318.
8
KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.唑来膦酸在人非小细胞癌临床前模型中的KRAS突变状态依赖性效应。
Oncotarget. 2016 Nov 29;7(48):79503-79514. doi: 10.18632/oncotarget.12806.
9
Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.下一代测序揭示了 EGFR-TKI 获得性耐药的 EGFR 突变型非小细胞肺癌中的新型耐药机制和分子异质性。
Lung Cancer. 2017 Nov;113:106-114. doi: 10.1016/j.lungcan.2017.09.005. Epub 2017 Sep 12.
10
Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.粘着斑激酶抑制剂与厄洛替尼联合使用在非小细胞肺癌中显示出增强的抗肿瘤活性。
PLoS One. 2016 Mar 10;11(3):e0150567. doi: 10.1371/journal.pone.0150567. eCollection 2016.

引用本文的文献

1
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells.通过靶向耐药细胞的选择性优势来延长肺癌对表皮生长因子受体(EGFR)抑制的反应。
Nat Commun. 2025 Aug 22;16(1):7853. doi: 10.1038/s41467-025-61788-w.
2
Harnessing CRISPR/Cas9 to overcome targeted therapy resistance in non‑small cell lung cancer: Advances and challenges (Review).利用CRISPR/Cas9克服非小细胞肺癌的靶向治疗耐药性:进展与挑战(综述)
Oncol Rep. 2025 Sep;54(3). doi: 10.3892/or.2025.8944. Epub 2025 Jul 11.
3
Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response.TP53突变型急性髓系白血病的化疗耐药需要甲羟戊酸副产物香叶基香叶基焦磷酸来诱导适应性应激反应。
Leukemia. 2025 Jul 9. doi: 10.1038/s41375-025-02668-6.
4
Advancements in Gene Therapy for Non-Small Cell Lung Cancer: Current Approaches and Future Prospects.非小细胞肺癌基因治疗的进展:当前方法与未来前景
Genes (Basel). 2025 May 12;16(5):569. doi: 10.3390/genes16050569.
5
Clonal dispersal is associated with tumor heterogeneity and poor prognosis in colorectal cancer.克隆性扩散与结直肠癌的肿瘤异质性和不良预后相关。
iScience. 2025 Apr 10;28(5):112403. doi: 10.1016/j.isci.2025.112403. eCollection 2025 May 16.
6
Applications and advancements of CRISPR-Cas in the treatment of lung cancer.CRISPR-Cas在肺癌治疗中的应用与进展
Front Cell Dev Biol. 2023 Dec 11;11:1295084. doi: 10.3389/fcell.2023.1295084. eCollection 2023.
7
Clonal tracking in cancer and metastasis.癌症和转移中的克隆追踪。
Cancer Metastasis Rev. 2024 Jun;43(2):639-656. doi: 10.1007/s10555-023-10149-4. Epub 2023 Nov 1.
8
Targeting the metastatic niche: Single-cell lineage tracing in prime time.靶向转移小生境:黄金时期的单细胞谱系追踪
iScience. 2023 Feb 10;26(3):106174. doi: 10.1016/j.isci.2023.106174. eCollection 2023 Mar 17.
9
Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer.非小细胞肺癌中对表皮生长因子受体靶向治疗获得性耐药和耐受性的机制
Cancers (Basel). 2023 Jan 13;15(2):504. doi: 10.3390/cancers15020504.
10
The continuing evolution of barcode applications: Functional toxicology to cell lineage.条码应用的持续发展:从功能毒理学到细胞谱系。
Exp Biol Med (Maywood). 2022 Dec;247(23):2119-2127. doi: 10.1177/15353702221121600. Epub 2022 Sep 16.

本文引用的文献

1
Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9.利用 CRISPR/Cas9 高效引入特定的纯合子和杂合子突变。
Nature. 2016 May 5;533(7601):125-9. doi: 10.1038/nature17664. Epub 2016 Apr 27.
2
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.肿瘤细胞可以沿着不同的进化路径对表皮生长因子受体抑制产生抗性。
Nat Med. 2016 Mar;22(3):262-9. doi: 10.1038/nm.4040. Epub 2016 Feb 1.
3
Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA.利用不对称供体 DNA 增强具有催化活性和非活性的 CRISPR-Cas9 的同源定向基因组编辑。
Nat Biotechnol. 2016 Mar;34(3):339-44. doi: 10.1038/nbt.3481. Epub 2016 Jan 20.
4
Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer.Apc基因恢复促进细胞分化并重建结直肠癌中的隐窝内环境稳定。
Cell. 2015 Jun 18;161(7):1539-1552. doi: 10.1016/j.cell.2015.05.033.
5
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.联合抑制表皮生长因子受体(EGFR)/丝裂原活化蛋白激酶(MEK)可预防EGFR突变型肺癌耐药的出现。
Cancer Discov. 2015 Sep;5(9):960-971. doi: 10.1158/2159-8290.CD-15-0063. Epub 2015 Jun 2.
6
Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR.为工作选择合适的工具:RNA干扰、转录激活样效应因子核酸酶还是规律成簇间隔短回文重复序列。
Mol Cell. 2015 May 21;58(4):575-85. doi: 10.1016/j.molcel.2015.04.028.
7
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.阿法替尼治疗表皮生长因子受体抑制剂耐药的非小细胞肺癌
N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817.
8
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.利用高复杂度条形码研究癌症治疗反应中的克隆动力学。
Nat Med. 2015 May;21(5):440-8. doi: 10.1038/nm.3841. Epub 2015 Apr 13.
9
Therapy-induced tumour secretomes promote resistance and tumour progression.治疗诱导的肿瘤分泌产物促进耐药性和肿瘤进展。
Nature. 2015 Apr 16;520(7547):368-72. doi: 10.1038/nature14336. Epub 2015 Mar 25.
10
Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells.提高 CRISPR-Cas9 诱导的哺乳动物细胞精确基因编辑中同源定向修复的效率。
Nat Biotechnol. 2015 May;33(5):543-8. doi: 10.1038/nbt.3198. Epub 2015 Mar 24.